Kcne3 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
KCNE3 modulates potassium channel function, forming channels with diverse properties. It is important for cardiac repolarization. Mutations are associated with arrhythmia disorders.
KCNE3 (Potassium Voltage-Gated Channel Subfamily E Regulatory Subunit 3) is a gene located on chromosome 11p15 that plays an important role in neurodegenerative disease. Mutations in KCNE3 are associated with Arrhythmia, Brugada Syndrome. The gene is catalogued as NCBI Gene ID 10088 and OMIM 607333.
The KCNE3 gene encodes a protein involved in key neuronal functions. It is expressed in Heart, Skeletal muscle.
Expression data is available from the Allen Human Brain Atlas.
KCNE3 mutations are linked to the following conditions:
Arrhythmia, Brugada Syndrome
The study of Kcne3 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Potassium channels in neurons: Hille B. Ionic Channels of Excitable Membranes. 3rd ed. Sinauer Associates; 2001.
- KCNN channels (SK/IK): Stocker M. Nat Rev Neurosci. 2004;5(10):758-770. PMID:15378036
- KCa channels in neurodegeneration: Shah NH, et al. Nat Rev Neurosci. 2018;19(9):485-498. PMID:30046008
- Potassium channel dysfunction in AD: Angulo E, et al. J Neurosci. 2004;24(20):4676-4682. PMID:15140932
- Potassium channels and neuronal excitability: Bean BP. Nat Rev Neurosci. 2007;8(6):451-465. PMID:17541432
- SK channel activators as therapy: Ehling P, et al. Nat Rev Drug Discov. 2020;19(11):773-789. PMID:32877965
- Potassium channels in PD: Lüscher C, Slesinger PA. Nat Rev Neurosci. 2010;11(9):569-579. PMID:20649637
- Ion channel therapeutics: Garnock-Jones KP. CNS Drugs. 2017;31(5):383-392. PMID:28447065
- Stocker M. Calcium-activated potassium channels: molecular diversity and function. Physiological Reviews. 2004;84(3):903-934. PMID:15269336
- Bhattacharjee A, Kaczmarek LK. Slack channels: from genes to function. Cell Calcium. 2005;38(3-4):237-246. PMID:16102830
- Passmore GM, Reilly JM, Wang Z, et al. Functional analysis of KCa3.1 channel blockers in sensory neurons. European Journal of Pharmacology. 2012;691:28-36. PMID:22705073
- Wulff H, Castle NA, Pardo LA. Voltage-gated potassium channels as therapeutic targets. Nature Reviews Drug Discovery. 2009;8(12):982-1001. PMID:19960002
- Kohler M, Hirschberg B, Bond CT, et al. Small-conductance, calcium-activated potassium channels from mammalian brain. Science. 1996;273(5282):1709-1714. PMID:8781166
- Herson PS, Brody DL, Kaczmarek LK. In quest of the cardiac sK channel. Cardiovascular Research. 1999;42(2):377-385. PMID:10510335
- Mathie A, Wooltorton JR, Watkins CS. Voltage-gated potassium channels as therapeutic targets. CNS Drugs. 1998;9(5):335-346.
- Rudy B, McBain CJ. Kv3 channels: voltage-gated K+ channels designed for high-frequency repetitive firing. Trends in Neurosciences. 2001;24(9):517-526. PMID:11530637